AUD18.33
1.27% day before yesterday
Australia, Aug 22, 08:10 am CET
ISIN
AU000000TLX2
Symbol
TLX

Telix Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Telix Pharmaceuticals Classifications & Recommendation:

Buy
87%
Hold
13%

Telix Pharmaceuticals Price Target

Target Price AUD34.68
Price AUD18.33
Potential
Number of Estimates 10
10 Analysts have issued a price target Telix Pharmaceuticals 2026 . The average Telix Pharmaceuticals target price is AUD34.68. This is higher than the current stock price. The highest price target is
AUD37.80 106.22%
register free of charge
, the lowest is .
A rating was issued by 15 analysts: 13 Analysts recommend Telix Pharmaceuticals to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Telix Pharmaceuticals stock has an average upside potential 2026 of . Most analysts recommend the Telix Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million AUD 783.21 1,242.00
55.85% 58.58%
Net Margin 6.37% 14.58%
514.81% 128.75%

13 Analysts have issued a sales forecast Telix Pharmaceuticals 2025 . The average Telix Pharmaceuticals sales estimate is

AUD1.2b
Unlock
. This is
58.58% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
AUD1.4b 81.05%
Unlock
, the lowest is
AUD783m 0.02%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 AUD783m 55.85%
2025
AUD1.2b 58.58%
Unlock
2026
AUD1.6b 25.85%
Unlock
2027
AUD1.9b 19.96%
Unlock
2028
AUD2.1b 14.24%
Unlock
2029
AUD2.2b 3.78%
Unlock
2030
AUD2.5b 13.32%
Unlock
2031
AUD2.8b 12.27%
Unlock
2032
AUD3.1b 9.37%
Unlock

11 Telix Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Telix Pharmaceuticals net profit estimate is

AUD181m
Unlock
. This is
262.70% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
AUD457m 815.28%
Unlock
, the lowest is
AUD68.9m 38.00%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 AUD49.9m 858.16%
2025
AUD181m 262.70%
Unlock
2026
AUD291m 60.48%
Unlock
2027
AUD376m 29.24%
Unlock
2028
AUD305m 18.65%
Unlock
2029
AUD369m 20.65%
Unlock
2030
AUD428m 16.22%
Unlock
2031
AUD425m 0.77%
Unlock
2032
AUD505m 18.75%
Unlock

Net Margin

2024 6.37% 514.81%
2025
14.58% 128.75%
Unlock
2026
18.59% 27.50%
Unlock
2027
20.03% 7.75%
Unlock
2028
14.26% 28.81%
Unlock
2029
16.58% 16.27%
Unlock
2030
17.00% 2.53%
Unlock
2031
15.03% 11.59%
Unlock
2032
16.32% 8.58%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share AUD 0.14 0.54
600.00% 285.71%
P/E 33.89
EV/Sales 4.83

11 Analysts have issued a Telix Pharmaceuticals forecast for earnings per share. The average Telix Pharmaceuticals EPS is

AUD0.54
Unlock
. This is
260.00% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
AUD1.37 813.33%
Unlock
, the lowest is
AUD0.21 40.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 AUD0.14 600.00%
2025
AUD0.54 285.71%
Unlock
2026
AUD0.87 61.11%
Unlock
2027
AUD1.12 28.74%
Unlock
2028
AUD0.91 18.75%
Unlock
2029
AUD1.10 20.88%
Unlock
2030
AUD1.28 16.36%
Unlock
2031
AUD1.27 0.78%
Unlock
2032
AUD1.51 18.90%
Unlock

P/E ratio

Current 122.20 4.48%
2025
33.89 72.27%
Unlock
2026
21.12 37.68%
Unlock
2027
16.34 22.63%
Unlock
2028
20.08 22.89%
Unlock
2029
16.65 17.08%
Unlock
2030
14.32 13.99%
Unlock
2031
14.44 0.84%
Unlock
2032
12.16 15.79%
Unlock

Based on analysts' sales estimates for 2025, the Telix Pharmaceuticals stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 7.66 21.84%
2025
4.83 36.97%
Unlock
2026
3.84 20.54%
Unlock
2027
3.20 16.64%
Unlock
2028
2.80 12.46%
Unlock
2029
2.70 3.64%
Unlock
2030
2.38 11.75%
Unlock
2031
2.12 10.93%
Unlock
2032
1.94 8.57%
Unlock

P/S ratio

Current 7.82 21.37%
2025
4.93 36.94%
Unlock
2026
3.92 20.54%
Unlock
2027
3.27 16.64%
Unlock
2028
2.86 12.47%
Unlock
2029
2.76 3.64%
Unlock
2030
2.43 11.75%
Unlock
2031
2.17 10.93%
Unlock
2032
1.98 8.56%
Unlock

Current Telix Pharmaceuticals Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
WILSONS
Locked
Locked
Locked Jul 17 2025
JEFFERIES
Locked
Locked
Locked Jul 16 2025
BELL POTTER SECURITIES
Locked
Locked
Locked Jul 14 2025
TD COWEN
Locked
Locked
Locked Jun 11 2025
WILLIAM BLAIR & COMPANY
Locked
Locked
Locked Jun 03 2025
TAYLOR COLLISON
Locked
Locked
Locked May 11 2025
WILSONS
Locked
Locked
Locked Apr 07 2025
Analyst Rating Date
Locked
WILSONS:
Locked
Locked
Jul 17 2025
Locked
JEFFERIES:
Locked
Locked
Jul 16 2025
Locked
BELL POTTER SECURITIES:
Locked
Locked
Jul 14 2025
Locked
TD COWEN:
Locked
Locked
Jun 11 2025
Locked
WILLIAM BLAIR & COMPANY:
Locked
Locked
Jun 03 2025
Locked
TAYLOR COLLISON:
Locked
Locked
May 11 2025
Locked
WILSONS:
Locked
Locked
Apr 07 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today